- Home
- HOV vs OCS Comparison
HOV vs OCS Comparison
Compare HOV & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- OCS
- Stock Information
- Founded
- HOV 1959
- OCS 2003
- Country
- HOV United States
- OCS Switzerland
- Employees
- HOV N/A
- OCS N/A
- Industry
- HOV Homebuilding
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- OCS Health Care
- Exchange
- HOV Nasdaq
- OCS Nasdaq
- Market Cap
- HOV 877.2M
- OCS 1.0B
- IPO Year
- HOV N/A
- OCS N/A
- Fundamental
- Price
- HOV $125.65
- OCS $19.00
- Analyst Decision
- HOV Hold
- OCS Strong Buy
- Analyst Count
- HOV 1
- OCS 4
- Target Price
- HOV $120.00
- OCS $42.50
- AVG Volume (30 Days)
- HOV 100.8K
- OCS 104.4K
- Earning Date
- HOV 12-04-2025
- OCS 11-10-2025
- Dividend Yield
- HOV N/A
- OCS N/A
- EPS Growth
- HOV N/A
- OCS N/A
- EPS
- HOV 20.64
- OCS N/A
- Revenue
- HOV $3,140,315,000.00
- OCS $991,999.00
- Revenue This Year
- HOV N/A
- OCS $32.89
- Revenue Next Year
- HOV $6.78
- OCS $1,043.16
- P/E Ratio
- HOV $6.08
- OCS N/A
- Revenue Growth
- HOV 7.83
- OCS N/A
- 52 Week Low
- HOV $81.15
- OCS $14.00
- 52 Week High
- HOV $202.00
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- HOV 48.17
- OCS 40.86
- Support Level
- HOV $119.19
- OCS $19.02
- Resistance Level
- HOV $126.10
- OCS $19.68
- Average True Range (ATR)
- HOV 5.10
- OCS 0.73
- MACD
- HOV 0.15
- OCS -0.27
- Stochastic Oscillator
- HOV 39.37
- OCS 0.65
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.